Skip to main content
Journal cover image

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.

Publication ,  Journal Article
Wong, MK; Kaufman, HL; Daniels, GA; McDermott, DF; Aung, S; Lowder, JN; Morse, MA
Published in: J Immunother Cancer
2014

Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.

Duke Scholars

Published In

J Immunother Cancer

DOI

ISSN

2051-1426

Publication Date

2014

Volume

2

Start / End Page

20

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wong, M. K., Kaufman, H. L., Daniels, G. A., McDermott, D. F., Aung, S., Lowder, J. N., & Morse, M. A. (2014). Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer, 2, 20. https://doi.org/10.1186/2051-1426-2-20
Wong, Michael K., Howard L. Kaufman, Gregory A. Daniels, David F. McDermott, Sandra Aung, James N. Lowder, and Michael A. Morse. “Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.J Immunother Cancer 2 (2014): 20. https://doi.org/10.1186/2051-1426-2-20.
Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, et al. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer. 2014;2:20.
Wong, Michael K., et al. “Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.J Immunother Cancer, vol. 2, 2014, p. 20. Pubmed, doi:10.1186/2051-1426-2-20.
Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer. 2014;2:20.
Journal cover image

Published In

J Immunother Cancer

DOI

ISSN

2051-1426

Publication Date

2014

Volume

2

Start / End Page

20

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology